Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital

Authors: Lemuel L Dent, Dana R Marshall, Siddharth Pratap, Robert B Hulette

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Multidrug resistant Acinetobacter baumannii, (MRAB) is an important cause of hospital acquired infection. The purpose of this study is to determine the risk factors for MRAB in a city hospital patient population.

Methods

This study is a retrospective review of a city hospital epidemiology data base and includes 247 isolates of Acinetobacter baumannii (AB) from 164 patients. Multidrug resistant Acinetobacter baumannii was defined as resistance to more than three classes of antibiotics. Using the non-MRAB isolates as the control group, the risk factors for the acquisition of MRAB were determined.

Results

Of the 247 AB isolates 72% (177) were multidrug resistant. Fifty-eight percent (143/247) of isolates were highly resistant (resistant to imipenem, amikacin, and ampicillin-sulbactam). Of the 37 patients who died with Acinetobacter colonization/infection, 32 (86%) patients had the organism recovered from the respiratory tract. The factors which were found to be significantly associated (p ≤ 0.05) with multidrug resistance include the recovery of AB from multiple sites, mechanical ventilation, previous antibiotic exposure, and the presence of neurologic impairment. Multidrug resistant Acinetobacter was associated with significant mortality when compared with sensitive strains (p ≤ 0.01). When surgical patients (N = 75) were considered separately, mechanical ventilation and multiple isolates remained the factors significantly associated with the development of multidrug resistant Acinetobacter. Among surgical patients 46/75 (61%) grew a multidrug resistant strain of AB and 37/75 (40%) were resistant to all commonly used antibiotics including aminoglycosides, cephalosporins, carbepenems, extended spectrum penicillins, and quinolones. Thirty-five percent of the surgical patients had AB cultured from multiple sites and 57% of the Acinetobacter isolates were associated with a co-infecting organism, usually a Staphylococcus or Pseudomonas. As in medical patients, the isolation of Acinetobacter from multiple sites and the need for mechanical ventilation were significantly associated with the development of MRAB.

Conclusions

The factors significantly associated with MRAB in both the general patient population and surgical patients were mechanical ventilation and the recovery of Acinetobacter from multiple anatomic sites. Previous antibiotic use and neurologic impairment were significant factors in medical patients. Colonization or infection with MRAB is associated with increased mortality.
Literature
1.
go back to reference García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jiménez-Jiménez FJ, Monterrubio-Villar J, Gili-Miner M: Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med. 1999, 27 (9): 1794-1799. 10.1097/00003246-199909000-00015.CrossRefPubMed García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jiménez-Jiménez FJ, Monterrubio-Villar J, Gili-Miner M: Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med. 1999, 27 (9): 1794-1799. 10.1097/00003246-199909000-00015.CrossRefPubMed
2.
go back to reference Falagas M E, Rafailidis PI: Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Critical Care. 2007, 11 (3): 134-136. 10.1186/cc5911.CrossRefPubMedPubMedCentral Falagas M E, Rafailidis PI: Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Critical Care. 2007, 11 (3): 134-136. 10.1186/cc5911.CrossRefPubMedPubMedCentral
3.
go back to reference Jamulitrat S, Arunpan P, Phainuphong P: Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection. J Med Assoc Thai. 2009, 92 (3): 413-419.PubMed Jamulitrat S, Arunpan P, Phainuphong P: Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection. J Med Assoc Thai. 2009, 92 (3): 413-419.PubMed
4.
go back to reference Falagas ME, Koletsi PK, Bliziotis IA: The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006, 55 (Pt 12): 1615-1617. Falagas ME, Koletsi PK, Bliziotis IA: The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006, 55 (Pt 12): 1615-1617.
5.
go back to reference Kluytmans-Vandenbergh M, Kluytmans J, Voss A: Dutch guideline for preventing nosocomial transmission of highly resistant microorganisms (HRMO). Infection. 2005, 5/6: 309-313. 10.1007/s15010-005-5079-z.CrossRef Kluytmans-Vandenbergh M, Kluytmans J, Voss A: Dutch guideline for preventing nosocomial transmission of highly resistant microorganisms (HRMO). Infection. 2005, 5/6: 309-313. 10.1007/s15010-005-5079-z.CrossRef
6.
go back to reference Seifert H, Strate A, Pulverer G: Nosocomial bacteremia due to Acinetobacter baumannii: Clinical features, epidemiology, and predictors of mortality. Medicine. 1995, 74 (6): 340-349. 10.1097/00005792-199511000-00004.CrossRefPubMed Seifert H, Strate A, Pulverer G: Nosocomial bacteremia due to Acinetobacter baumannii: Clinical features, epidemiology, and predictors of mortality. Medicine. 1995, 74 (6): 340-349. 10.1097/00005792-199511000-00004.CrossRefPubMed
7.
go back to reference Baran G, Erbay A, Bodur H, Ongürü P, Akinci E, Balaban N, Cevik MA: Risk factors for nosocomial imipenem resistant Acinetobacter baumannii infections. Int J Infect Dis. 2008, 12 (1): 16-21. 10.1016/j.ijid.2007.03.005.CrossRefPubMed Baran G, Erbay A, Bodur H, Ongürü P, Akinci E, Balaban N, Cevik MA: Risk factors for nosocomial imipenem resistant Acinetobacter baumannii infections. Int J Infect Dis. 2008, 12 (1): 16-21. 10.1016/j.ijid.2007.03.005.CrossRefPubMed
8.
go back to reference Falagas ME, Kopterides P: Risk factors for the isolation of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systemic review of the literature. J Hosp Inf. 2006, 64 (1): 7-15. 10.1016/j.jhin.2006.04.015.CrossRef Falagas ME, Kopterides P: Risk factors for the isolation of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systemic review of the literature. J Hosp Inf. 2006, 64 (1): 7-15. 10.1016/j.jhin.2006.04.015.CrossRef
9.
go back to reference Mahgoub S, Ahmed J, Glatt AE: Underlying characteristics of patients harboring highly resistant Acinetobacter baumannii. Am J Infect Control. 2002, 30 (7): 386-390. 10.1067/mic.2002.122648.CrossRefPubMed Mahgoub S, Ahmed J, Glatt AE: Underlying characteristics of patients harboring highly resistant Acinetobacter baumannii. Am J Infect Control. 2002, 30 (7): 386-390. 10.1067/mic.2002.122648.CrossRefPubMed
10.
go back to reference Villers D, Espaze E, Coste-Burel M, Giauffret F, Ninin E, Nicolas F, Richet H: Nosocomial Acinetobacter baumannii infections: Microbiological and clinical epidemiology. Ann of Int Med. 1998, 129 (3): 182-189.CrossRef Villers D, Espaze E, Coste-Burel M, Giauffret F, Ninin E, Nicolas F, Richet H: Nosocomial Acinetobacter baumannii infections: Microbiological and clinical epidemiology. Ann of Int Med. 1998, 129 (3): 182-189.CrossRef
11.
go back to reference Maragakis LL, Tucker MG, Miller RG, Carroll KC, Perl TM: Incidence and prevalence of multidrug-resistant Acinetobacter using targeted active surveillance cultures. JAMA. 2008, 299 (21): 2513-2514. 10.1001/jama.299.21.2513.CrossRefPubMed Maragakis LL, Tucker MG, Miller RG, Carroll KC, Perl TM: Incidence and prevalence of multidrug-resistant Acinetobacter using targeted active surveillance cultures. JAMA. 2008, 299 (21): 2513-2514. 10.1001/jama.299.21.2513.CrossRefPubMed
12.
go back to reference Nseir S, Di Pompeo C, Cavestri B, Jozefowicz E, Nyunga M, Soubrier S, Roussel-Delvallez M, Saulnier F, Mathieu D, Durocher A: Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome. Crit Care Med. 2006, 34 (12): 2959-2966.CrossRefPubMed Nseir S, Di Pompeo C, Cavestri B, Jozefowicz E, Nyunga M, Soubrier S, Roussel-Delvallez M, Saulnier F, Mathieu D, Durocher A: Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome. Crit Care Med. 2006, 34 (12): 2959-2966.CrossRefPubMed
13.
go back to reference Davis KA, Moran KA, McAllister CK, Gray PJ: Multi-drug-resistant Acinetobacter extremity infections in soldiers. Emerg Inf Dis. 2005, 11 (8): 1218-1224.CrossRef Davis KA, Moran KA, McAllister CK, Gray PJ: Multi-drug-resistant Acinetobacter extremity infections in soldiers. Emerg Inf Dis. 2005, 11 (8): 1218-1224.CrossRef
14.
go back to reference Maragakis LL, Cosgrove SE, Song X, Kim D, Rosenbaum P, Ciesla N, Srinivasan A, Ross T, Carroll K, Perl TM: An Outbreak of multidrug-resistant Acinetobacter baumannii associated with pulsatile lavage wound treatment. JAMA. 2004, 292 (24): 3006-3011. 10.1001/jama.292.24.3006.CrossRefPubMed Maragakis LL, Cosgrove SE, Song X, Kim D, Rosenbaum P, Ciesla N, Srinivasan A, Ross T, Carroll K, Perl TM: An Outbreak of multidrug-resistant Acinetobacter baumannii associated with pulsatile lavage wound treatment. JAMA. 2004, 292 (24): 3006-3011. 10.1001/jama.292.24.3006.CrossRefPubMed
15.
go back to reference Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002, 165: 867-903.CrossRefPubMed Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002, 165: 867-903.CrossRefPubMed
16.
go back to reference Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, Gallego-Lara SL, Madrazo-Osuna J: Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003, 36: 1111-1118. 10.1086/374337.CrossRefPubMed Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, Gallego-Lara SL, Madrazo-Osuna J: Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003, 36: 1111-1118. 10.1086/374337.CrossRefPubMed
17.
go back to reference Aybar Türkoğlu M, Topeli Iskit A: Ventilator associated pneumonia caused by high risk microorganisms: a matched case control study. Tuberk Toraks. 2008, 56 (2): 139-149.PubMed Aybar Türkoğlu M, Topeli Iskit A: Ventilator associated pneumonia caused by high risk microorganisms: a matched case control study. Tuberk Toraks. 2008, 56 (2): 139-149.PubMed
18.
go back to reference Mai MH, Tsai HC, Lee SS, Wang YH, Chen YS, Wann SR, Liu YC: Multi-drug-resistant Acinetobacter baumannii in ventilator-associated pneumonia at a medical center in southern Taiwan. J Microbiol Immunol Infect. 2007, 40 (5): 401-405.PubMed Mai MH, Tsai HC, Lee SS, Wang YH, Chen YS, Wann SR, Liu YC: Multi-drug-resistant Acinetobacter baumannii in ventilator-associated pneumonia at a medical center in southern Taiwan. J Microbiol Immunol Infect. 2007, 40 (5): 401-405.PubMed
19.
go back to reference Peleg AY, Seifert H, Paterson D: Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin Microbiol Reviews. 2008, 538-582. 10.1128/CMR.00058-07. Peleg AY, Seifert H, Paterson D: Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin Microbiol Reviews. 2008, 538-582. 10.1128/CMR.00058-07.
Metadata
Title
Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital
Authors
Lemuel L Dent
Dana R Marshall
Siddharth Pratap
Robert B Hulette
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-196

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.